11
March 2021
Alphamab Oncology to Present Clinical Data of PD-L1/CTLA-4 Bispecific Antibody KN046 Combined with Nab-paclitaxel in the Treatment of mTNBC at the AACR 2021
The results show that KN046 is well tolerated and effective as a treatment for advanced triple-negative breast cancer, especially in PD-L1-positive TNBC patients, showing a progression-free survival (...